ArticleThe patient2026
Preferences for Parkinson's Disease Treatments: A Scoping Literature Review.
Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Preferences and Priorities in Advanced Parkinson's Disease: A Discrete Choice Experiment.Neurology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that significantly impact quality of life. As the disease advances, treatment options expand from oral medications to include device-aided therapies, which differ widely in their mechanisms, invasiveness, and impact on daily life. These therapies have distinct attributes that may align differently with individual patient preferences; therefore, understanding such preferences is crucial for informed, shared clinical decision making. This scoping review synthesizes quantitative evidence on treatment preferences among people with Parkinson's disease (PwP), highlighting research gaps on key attributes.
methodsA systematic search of PubMed and Embase (January 2026) identified studies using quantitative stated-preference methods-discrete choice experiments, best-worst scaling, conjoint analysis, or threshold techniques-with PwP, care partners, or healthcare professionals. Twelve studies met inclusion criteria.
resultsTreatment efficacy-particularly increased 'ON time' (periods without troublesome dyskinesia)-and treatment modality were the strongest drivers of preferences. PwP favored non-invasive treatments, such as oral or sublingual formulations, over surgical options like deep brain stimulation. Convenience factors, including pill burden and device management frequency, also influenced preferences but were generally secondary to efficacy and modality. Safety attributes, such as risk of depression or cognitive decline, were important but often outweighed by perceived benefits in symptom control. No studies assessed care partners' preferences for modalities such as subcutaneous infusions.
conclusionsPwP prioritize treatment efficacy and non-invasive modalities, with convenience and safety considered secondary. Further research should explore preferences for new treatment modalities and include care partners' perspectives to optimize treatment planning and outcomes in PD care.
Identifiers
42487050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.